AKYLA/ Financials
MarketsScreenerFinancialsResearchChat
Equity / IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES
Anbio Biotechnology Class A Ordinary Shares
XNAS · usd
SIC 2835 · IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES
FIGI AK-4BB66EB512
3.81▲ 0.10 (2.70%)
As of 2026-10-23
Price / Volume
Valuation
Market Cap
Enterprise Value
Trailing P/E
Price / Sales
EV / Revenue
EV / EBITDA
—
Financial Highlights
Revenue (TTM)
Net Income (TTM)
EBITDA
—
Diluted EPS (TTM)
EBITDA Margin
—
Net Debt
Trading Information
Previous Close
3.71
Day's Range
3.47 – 3.92
52-Week Range
3.09 – 44.73
Volume
25.8K
Avg Volume
127.2K
Share Statistics
Shares Outstanding
Employees
27
Exchange
XNAS
Listed
2025-02-19
Share count as of December 31, 2025

Anbio Biotechnology Class A Ordinary Shares (NNNN) Financial Statements

View
Income Statement
Detail
Standard
Period
Quarterly
Loading Income Statement…
Key questions about Anbio Biotechnology Class A Ordinary Shares (NNNN)
What is Anbio Biotechnology Class A Ordinary Shares's Market Cap?
Anbio Biotechnology Class A Ordinary Shares's Market Cap is $548.2M, based on as-reported figures from SEC (XBRL) filings.
What is Anbio Biotechnology Class A Ordinary Shares's Enterprise Value?
Anbio Biotechnology Class A Ordinary Shares's Enterprise Value is $536.3M, based on as-reported figures from SEC (XBRL) filings.
What is Anbio Biotechnology Class A Ordinary Shares's Trailing P/E?
Anbio Biotechnology Class A Ordinary Shares's Trailing P/E is 85.6×, based on as-reported figures from SEC (XBRL) filings.
What is Anbio Biotechnology Class A Ordinary Shares's Price / Sales?
Anbio Biotechnology Class A Ordinary Shares's Price / Sales is 63.4×, based on as-reported figures from SEC (XBRL) filings.
What is Anbio Biotechnology Class A Ordinary Shares's EV / Revenue?
Anbio Biotechnology Class A Ordinary Shares's EV / Revenue is 62.0×, based on as-reported figures from SEC (XBRL) filings.
What is Anbio Biotechnology Class A Ordinary Shares's Revenue (TTM)?
Anbio Biotechnology Class A Ordinary Shares's Revenue (TTM) is $8.6M, based on as-reported figures from SEC (XBRL) filings.
What is Anbio Biotechnology Class A Ordinary Shares's Net Income (TTM)?
Anbio Biotechnology Class A Ordinary Shares's Net Income (TTM) is $6.4M, based on as-reported figures from SEC (XBRL) filings.
What is Anbio Biotechnology Class A Ordinary Shares's Diluted EPS (TTM)?
Anbio Biotechnology Class A Ordinary Shares's Diluted EPS (TTM) is 0.04, based on as-reported figures from SEC (XBRL) filings.
What is Anbio Biotechnology Class A Ordinary Shares's Net Debt?
Anbio Biotechnology Class A Ordinary Shares's Net Debt is -$11.9M, based on as-reported figures from SEC (XBRL) filings.
Akyla / Financials · NNNNAs-filed SEC (XBRL) data
No Quarterly data available for this company — showing Annual instead. This company files annual reports only — foreign private issuers (Form 20-F / 40-F) are not required to file quarterly reports, so no quarterly figures exist to show.
Showing the most recent year. Subscribe for full statement history.
Income Statement(in thousands of USD, except per-share data)
Source: Akyla.ai
Line ItemDec 31, 2025Dec 31, 2024Dec 31, 2023Dec 31, 2022
Total Revenues
YoY growth+5.6%
Cost of Revenues
Gross Profit
% of revenue87.2%
Operating Expenses
Selling, general and administrative
Research and development
Total operating expenses
% of revenue20.5%
Income from operations
% of revenue66.7%
Other Income
Interest and investment income
Foreign exchange gain
Others, net
Total other income
Income before provision for income taxes
Provision for income taxes
Net income
% of revenue74.1%
Basic earnings per Class A share (in Dollars per share)
Diluted earnings per Class A share (in Dollars per share)